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Abstract
Background: Recent reports document an increasing incidence of new Gram-negative pathogens such as
Stenotrophomonas maltophilia and Alcaligenes xylosoxidans isolated from patients with Cystic Fibrosis, along with an
increase in common Gram-negative pathogens such as Pseudomonas aeruginosa and Burkholderia cepacia complex.
Furthermore, the increase in multidrug-resistance of such organisms makes the therapeutic management of these
patients more problematic. Therefore, careful isolation and identification, and accurate studies of susceptibility to
antibiotics are critical for predicting the spread of strains, improving therapeutic measures and facilitating our
understanding of the epidemiology of emerging pathogens. The first aim of this study was to determine the
incidence and the prevalence of colonization by Gram-negative organisms isolated from respiratory samples of
Cystic Fibrosis patients in the Regional Referral Cystic Fibrosis Centre of Naples; the second was to evaluate the
spectrum of multidrug-resistance of these organisms.
Methods: Patients (n = 300) attending the Regional Cystic Fibrosis Unit were enrolled in this study over 3 years.
Sputum was processed for microscopic tests and culture. An automated system, Phoenix (Becton Dickinson,
Sparks, Maryland, USA), was used for phenotypic identification of all strains; the API 20 NE identification system
(bioMérieux, Marcy l'Etoile, France) was used when the identification with the Phoenix system was inaccurate. A
PCR-RFLP method was used to characterize the organisms in the Burkholderia cepacia complex. A
chemosusceptibility test on microbroth dilutions (Phoenix) was used. Primary outcomes such as FEV1 were
correlate with different pathogens.
Results: During the period of study, 40% of patients was infected by Pseudomonas aeruginosa, 7% by Burkholderia
cepacia complex, 11% by Stenotrophomonas maltophilia and 7% by Alcaligenes xylosoxidans. Of the strains isolated,
460 were multidrug-resistant. Multiresistant were Pseudomonas aeruginosa and Burkholderia cepacia complex.
Conclusion: The results confirm previously reported data; in particular, they show an increase the isolation of
non-fermentative Gram-negative bacteria in Cystic Fibrosis patients. They also demonstrate increased resistance
to antibiotics. Beta-lactams are rarely effective, with exception of ceftazidime, which is the most efficacious agent
against multiresistant strains. Aminoglycosides and quinolones are poorly efficacious.
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Background
Cystic Fibrosis (CF) is the most common life-shortening
autosomal recessive disease in the white population and
afflicts over 30.000 persons in the United States [1]. While
the genetic defect in CF is known, the relationship
between the abnormal CFTR protein and chronic pulmo-
nary disease has recently become more clear [2]. A hall-
mark of CF is chronic respiratory infection which may
start very early in the life of these patients. Since the early
description of CF, pulmonary infection has been recog-
nized as having the greatest role in morbidity and mortal-
ity leading to premature death in 90% of patients. The
underlying basic defect in CF, the restriction of infection
to the lung and the chronic nature of infection character-
ize the vicious cycle of inflammation. Pseudomonas aerugi-
nosa (PA) has been the most common pathogen in the
lower airways of CF patients during the last 3 decades.
With the improved survival, new emergent pathogens in
the CF lung as Burkholderia cepacia complex (Bcc), Stenotro-
phomonas maltophilia (SM) and Alcaligenes xylosoxidans
(AX) have been detected in the last years [3-6]. While it is
recognized that CF patients with Bcc infection can have a
worsening of lung function, the relationship between SM
and clinical outcome remains to be debated [7]. It is pos-
sible to prevent or delay the onset of chronic infections in
most patients with CF by eliminating cross-infections and
by early aggressive antibiotic treatment of the positive
sputum culture. Because of the insidious nature of some
of the lower respiratory tract infections, frequent bacterio-
logical investigations of sputum or tracheal secretions are
necessary in order to apply hygienic measures in the care
centers, segregating the infected and the non-infected
patients in different wards as well as to prevent or post-
pone chronic pulmonary infections [8,9]. This is the rea-
son why a continuous survey of microbiological data is
mandatory in order to identify most common pathogens
in each single centre in terms of annual incidence and
prevalence related to primary clinical outcome. The first
aim of our study was to evaluate the incidence and preva-
lence of Gram-negative infection in a CF cohort study.
Recently it has been reported an increasing antibiotic
resistance against the most commonly used antibiotics in
the CF patients, above all related to emergence of hyper-
mutable bacteria. This implies difficulties on therapeutic
approach [10,11]. Moreover current evidence does not
provide a clear relationship between clinical impact and
multidrug-resistance.
The second aim of our study was to evaluate a three-year
trend of multidrug-resistant strains isolated in our Centre
and if this contributes to a greater morbidity in these
patients.
Methods
Study design
Data were collected by a retrospective analysis of database
case records of 300 patients (140 males, 160 females;
mean age 16.21 years; range 0.5–50 years) attending reg-
ularly the Regional Referral CF Centre of Naples between
January 2002 and December 2004. Patients over 6 years of
age had at least one lung function evaluation as measured
by forced expiratory volume in 1 sec (FEV1) during each
year of observation at clinic visit and/or hospital discharge
expressed of a mean value of three years survey; oxygen
saturation measurement was noted for each visit. Regular
measure of weight, height, use of pancreatic enzymes,
number of CF related hospital admissions, number of
courses of intravenous antibiotics were obtained over the
observation period. For patients who had died these data
were ascertained for the 6 months preceding this event.
Genetic analysis was detected for each patient. Sputum or
bronchoaspirate swabs were obtained for each patient at
regular clinical attendances (patients were reviewed at 3
months intervals) as well as twice during hospital admis-
sion. Chronic PA infection was defined as persistent pres-
ence of three PA positive cultures for at last 6 consecutive
months [12]. Similarly, chronic pulmonary colonization
by Bcc and other emergent pathogens was defined. Stand-
ard laboratory tests for PA antigens were regularly tested
in our Centre but not applied to define chronic PA infec-
tion in this study.
The mean age of acquisition of chronic infection was reg-
istered. The yearly incidence of new chronic Gram-nega-
tive infection was computed. The prevalence of emergent
pathogens infections was calculated as the total number
of cases each year divided by the total number of patients
during the observation period.
Co-infection was defined as the sputum culture positive
for more than one organism. Patients were divided into
four groups positive for PA, Bcc, PA and Bcc, SM.
Comparison between the effect of PA and Bcc on decline
in lung function was performed during the observation
period, as well as between Bcc and SM.
Multidrug-resistance was assessed according to Cystic
Fibrosis Foundation for PA, extending it to all including
clinically relevant non-fermentative Gram-negative
strains [13].
PA multiresistant group was compared with its respective
control group consisting of patients with non multiresist-
ant PA infection.BMC Infectious Diseases 2006, 6:4 http://www.biomedcentral.com/1471-2334/6/4
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Processing of sputum samples, culture of organisms and 
phenotypic analysis
Natural or induced sputum samples, obtained from all
patients involved during period of the study, were mixed
with equal volumes of 1% dithiothreitol (Merck, Ger-
many) before incubation at 37°C for 30 min. All speci-
mens were examined microscopically and cultured. To
isolate Bcc, specimens were incubated on the oxidation-
fermentation base polymyxin B agar (Becton Dickinson)
and BCSA agar (bioMérieux) at 37°C for up to 72 h. All
isolates obtained from the samples were identified by the
Phoenix system; the API 20 NE identification system
(bioMerieux) was used when the identification with the
Phoenix system was inaccurate. Preparation of suspen-
sions, inoculations, incubation times, temperatures and
interpretation of reactions accorded with the manufac-
turer's instructions for each system.
Preparation of DNA from Bcc bacterial cultures
Liquid medium (25 ml Brain-Heart Broth, bioMérieux) in
a test tube was inoculated with Bcc strains obtained from
the solid culture medium. After incubation at 37°C with
120 shakes/min, at an optical density of 0.3–0.4 (absorb-
ance at 600 nm) the cells were harvested by centrifugation
at 4°C for 20 min at 3500 rpm. The pellet was resus-
pended in 4 ml of 50 mM D-glucose, 2 M Tris pH 7.5, 0.5
M EDTA pH 8. The cells were treated first with lysozyme
(10 mg/ml) for 15 min at room temperature and then
with 0.5 M EDTA, 10% SDS, followed by incubation with
Proteinase K (0.2 mg/ml) at 55°C for 2 h. DNA was
extracted with phenol, then with phenol and chloroform,
and finally with chloroform only. Then it was precipitated
with 0.1 volume Na-acetate and 2.5 volumes 99% etha-
nol. The pellet was rinsed three times with 70% ethanol,
dried and then dissolved in 1 ml of TE buffer pH 7.8. The
amount and purity of the bacterial genomic DNA were
assessed by measuring the absorbances at 260 and 280
nm [14,15].
Analysis for rec-A gene based identification
A DNA thermal cycler (PTC-100, MJ Research, Inc) was
used. The Bcc rec-A gene (1.040 bp) was amplified using
the primers BCR1 (tgaccgccgagaagagcaa) and BCR2 (ctct-
tcttcgtccatcgcctc), respectively, for the target 5' and 3' ends
of the rec-A gene locus. PCR was performed in a total vol-
ume of 100 µl containing 0.5 γ/λ DNA, 25 mM MgCl2, 25
mM dNTPs, 5.80 pmol/µl BCR1, 10.40 pmol/µl BCR2
and 5 U/µl Taq-polymerase. After initial heating at 94°C
for 1 min, 35 cycles of denaturation at 94°C for 30 sec,
annealing at 59°C for 45 sec and extension at 72°C for1
min were performed. The final extension step was at 72°C
for 5 min [14].
RFLP analysis of Bcc rec-A gene
For RFLP analysis, the Bcc rec-A gene amplicons (up to 40
µl) were digested with MnlI (New England Biolabs, Inc)
and HaeIII (New England Biolabs, Inc) restriction endo-
nucleases in the appropriate buffers at 37°C for 2 h [14].
Detection of PCR and RFLP products
The PCR-amplified products were analyzed by electro-
phoresis in 2% agarose gels. Restriction fragments were
resolved in 3% high-resolution Agarose 1000 (Invitrogen,
Inc) and the products were stained with ethidium bro-
mide and observed under UV [14].
Antimicrobial susceptibility testing method
To determine sensitivity to antimicrobial agents, a micro-
broth dilution assay using an automated Phoenix micro-
dilution system was utilized. This system is based on serial
dilutions of antibiotics and the MIC value is obtained
from interpretative criteria for susceptibility breakpoints.
Susceptibility criteria for the test method were in accord-
ance with National Committee for Clinical Laboratory
Standards Interpretative Criteria (Document M7-A4) [16].
Statistical analysis
Before analysis, data were screened for gross deviance
from normality. Since some groups of variables showed a
skeweness of >1 with a small sample size, non-parametric
tests for unpaired samples (Mann-Whitney test) were
applied throughout the study. FEV1 values of PA group
were compared with those belonging to Bcc group. FEV1
values of patients chronically infected with Bcc were com-
pared to those of SM colonized patients. The effect of
multidrug-resistant on FEV1 was analyzed within the PA
group.
p value of less than 0.05 was considered statistically signif-
icant.
Statistical analysis was performed using SPSS version
12.0.
Results
In the study time period, 3178 biological samples (spu-
tum and/or bronchoaspirate swabs) were analyzed; 1917
Gram-negative strains were isolated.
During the first year of observation PA was isolated in 120
patients (40%) (range 1–13 years); in this group 81/120
patients (67%) were chronic infected over the time study
period (mean age 8.7 years, range 1–19.9 years), with a
mean FEV1 of 68% of predicted values for age and sex
(range 15–122%). In 30/81 patients a multidrug-resist-
ance was documented.BMC Infectious Diseases 2006, 6:4 http://www.biomedcentral.com/1471-2334/6/4
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During the study period 21/300 patients (7%) were
infected by Bcc; molecular analysis of rec-A gene showed
that B. cenocepacia colonized 18 patient and three patients
were colonized by B. cepacia, B. stabilis and B. vietnamiensis
respectively, indicating that Bcc group most likely belongs
to B. cenocepacia. 18/21 patients have multidrug-resistant
Bcc chronic infection (mean age 10.8 years, range 7–16.6
years), with a mean FEV1 of 45% of predicted values for
age and sex (range 15–80%).
AX was detected in 21/300 patients (7%); 7 (mean age
13.5 years, range 12–15.8 years) have chronic infection
with a mean FEV1 of 53% of predicted values for age and
sex (range 28–79%). SM was found in 33/300 (11%); 8
(mean age 10.6 years, range 10–15 years) were chronically
infected with a mean FEV1 of 46% of predicted values for
age and sex (range 26–82%). In order to correlate chronic
PA and Bcc infection to lung function, patients chronically
infected were divided into four groups when only one
organism or co-infecting organisms were isolated.
Group 1: 65 CF patients with chronic PA infection were
identified (mean age at chronic PA infection 8.9 years;
range 1–19.9 years) with a mean FEV1 of 66.1% of pre-
dicted values for age and sex (range 19–122%)
Group 2: Bcc was isolated in 9 patients chronically
infected (mean age at chronic Bcc infection 11 years; range
7–16 years) with a mean FEV1 of 46.0% of predicted val-
ues for age and sex (range 20–80%).
Group 3: 9 patients were chronically co-infected by PA
and Bcc (mean age at chronic Bcc and PA infection 9.3
years; range 8–11.1 years) with a mean FEV1 of 46.6% of
predicted values for age and sex (range 15–71%).
Group 4: 7 patients (mean age 10.6 years, range 10–15
years) were chronically infected with PA and SM and 1
patient only with SM, with a mean FEV1 of 46% of pre-
dicted values for age and sex (range 26–82%).
The distribution of PA and Bcc incidence and prevalence
rate did not differ significantly during the study period.
Annual prevalence rate during each year of observation
ranged from 11% in 2002 to 17% in 2004 for SM.
Patients with Bcc chronic infection (Group 2 and Group
3) showed FEV1 mean value significantly lower than that
shown by patients with only PA chronic infection (Group
1) (Group 1 vs Group 2, p = 0.03; Group 1 vs Group 3, p
= 0.002). Co-infection with PA in Bcc patients did not lead
to significant variation of FEV1 mean values (Group 2 vs
Group 3, p = 0.9). Infection with SM did not effect lung
function of Bcc colonized patients.
In patients chronically PA colonized a significant decrease
of FEV1 mean value was found in patients (n = 30) with
PA multidrug-resistance (p < 0.001).
Other Gram-negative bacteria such as Comamonas acidovo-
rans, Comamonas testosteroni, Acinetobacter calcoaceticus and
Chryseobacterium indologenes were occasionally isolated
with the other organisms.
In table 1 total number of isolates, number and percent-
age of multiresistant strains for each type of bacteria are
reported.
Drug-multiresistance was found in 30 chronically PA
infected patients. Multiresistant Bcc strains were found in
18 patients, all chronically infected.
Susceptibility studies of multidrug-resistant pathogens
over the study period are summarized in Table 2. Beta-
lactam antibiotics showed moderate activity in vitro
against multiresistant bacteria of all species: only ceftazi-
dime seems to be the most efficacious antibiotic against
these types of bacteria (45.4%, 16.6%, 55.7% respectively
against Bcc, PA and AX) Therefore, ceftazidime was the
most active antibiotic against Bcc, while imipenem was
the most active in vitro against AX. Aminoglycosides are
Table 1: Distribution (number and percentage) of multidrug-resistant strains during the study period
Total strains Total strains Multidrug-resistant strains
No % No %
P.aeruginosa 1187 61.9 115 9.6
S.maltophilia 277 14.4 76 27.4
A.xylosoxidans 166 8.6 62 37.3
B. cepacia 14 0.7 14 100
B.cenocepacia 266 13.8 187 70.3
B.stabilis 4 0.2 4 100
B.vietnamiensis 3 0.1 2 66.7
1917 460 23.9BMC Infectious Diseases 2006, 6:4 http://www.biomedcentral.com/1471-2334/6/4
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Table 2: Percentage of Gram-negative isolated strains resistant to antibiotics tested.
Antibiotics
AMK AMP ATM FEP CTX CAZ CIP CHL COL GEN IPM LVX MEM NET PIP TZP RIF TET SXT
Bcc 98.46 100 81.82 81.82 86.62 45.45 89.06 87.50 100 98.46 91.30 83.33 65.63 96.97 65.15 51.52 93.94 100 76.92
SM 94,23 100 98.11 89.52 94.29 83.02 94.34 51.92 40 96.23 100 66.98 98.08 83.33 91.35 89.52 80 94.23 44.76
PA 56.16 100 20.55 15.71 78.08 16.67 44.44 89.39 4.88 61.64 38.46 49.32 38.36 46.30 43.06 20.55 96.23 96.49 100
AX 80 100 92.86 87.14 92.86 55.71 79.71 54.41 76.47 88.57 15.56 60 31.88 89.47 25.71 14.71 93.75 72.31 47.14
AMK = Amikacin; AMP = Ampicillin; ATM = Aztreonam; FEP= Cefepime; CTX= Cefotaxime; CAZ = Ceftazidime; CIP = Ciprofloxacin; CHL = 
Chloramphenicol; COL = Colistin; GEN = Gentamicin; IPM = Imipenem; LVX = Levofloxacin; MEM = Meropenem; NET = Netilmicin; PIP = Piperacillin; TZP 
= Piperacillin-tazobactam; RIF = Rifampin; TET = Tetracycline; SXT = Trimethoprim-sulfamethoxazole.
not very active against the bacterial strains isolated and
quinolones are relatively inactive against multiresistant
strains.
Discussion
This observational study examines the most prevalent
pathogens in a CF cohort of a single care Centre. PA is
identified more frequently in keeping with previous find-
ings [17].
Our study has confirmed that patients colonized with Bcc
and PA multidrug-resistant strains have a more rapid lung
decline with an associated increased number of hospital
admission (data not shown) [18]. With improved sur-
vival, new pathogens have emerged in the CF lung, partic-
ularly including SM and AX. The importance of this
colonization in CF patients is still unclear. Only a few pre-
viously case-control studies have been performed which
found no definitive evidence with a worse prognosis.
Treatment of chronic infection is controversial and not so
successful from a bacteriological point of view. However,
in many CF centres it is generally believed that the pro-
gressive tissue damage due to chronic inflammation
caused by opportunistic pathogens requires an early and
promptly regular treatment employing large dosage of
antibiotics. This approach has been generally shown to be
successful compared with courses of antibiotics adminis-
tered only for acute exacerbations. For this reason the
heavy antibiotic exposure in CF patients leads to multid-
rug-resistance due to different mechanisms [19].
Our observational study reports the experience of inci-
dence and prevalence of Gram-negative pathogens in our
CF care Centre that applies a long term intensive treat-
ment for chronic infection.
In our Centre overall percentage was 40%, 7% and 11%,
respectively for PA, Bcc and SM in 2002, according to data
worldwide [17] with no marked increase of prevalence
over the time study period, except for SM which has
shown an increasing prevalence from 11% to 17% during
the three years.
B. cenocepacia was the most prevalent genomovar of Bcc
recovered in our population. Moreover, patients were col-
onized only by single types of genomovar. Our data con-
firm that Bcc affects the clinical outcome of CF patients
above that PA, the most prevalent pathogen for this group
of patients [18]. There was a greater overall number of
deaths for patients with PA multidrug-resistant infection
in comparison with matched patients with PA infection
(36% vs 5.8%). The overall number of deaths in all multi-
drug-resistant Bcc patients was 33.3%. The factors influ-
encing the clinical course of a patient following
acquisition of chronic infection are clearly complex and
probably influenced by multiple factors, including host
response to pathogens. Probably multidrug-resistance can
influence prognosis and it is confirmed by our results that
show effect of PA multiresistance on deterioration of lung
function compared to matched patients with PA infection.
Our analysis indicates that many multiresistant strains are
found in our Unit: of the strains isolated, 23.9% are mul-
tiresistant, as showed in table 1. As previously reported,
our study also suggests that Bcc as well as SM and AX, is
resistant to many classes of antibiotics [20-22].
For this reason it could be a good clinical practice to inves-
tigate antibiotic susceptibility and synergy testing of
multidrug-resistant pathogens with conventional antibi-
otics. A multiple combination bacterial testing is recom-
mended for testing tobramycin and beta-lactams and/orBMC Infectious Diseases 2006, 6:4 http://www.biomedcentral.com/1471-2334/6/4
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third-generation cephalosporins, according to conven-
tional therapy.
Regular assessment of airway colonization is one of the
basic guidelines in clinical follow-up of these patients.
Identification of Gram-negative pathogens from the respi-
ratory tracts is critical not only for individual care but also
for the CF community. This is particularly true for such
bacteria as B. cenocepacia and other Bcc species because
they are highly transmissible and have a clinically signifi-
cant impact on mortality [23,24,13]. Molecular diagnostic
probes based on the PCR provide a rapid and frequently
highly discriminatory means of identifying infectious
organisms. Use of a PCR-RFLP method to establish the
bacterial genomovar of Bcc is very important; several stud-
ies have investigated potential differences in the clinical
impacts of different genomovars [22,25]. As described
above,  B. cenocepacia appears more likely than other
genomovars to be spread among patients and to be asso-
ciated with outbreaks [26,27]. The small number of our
data does not consent to confirm these results.
It is not clear whether new pathogens could compromise
the clinical status of CF patients. Large-scale clinical trials
are needed to assess their potential pathogenic role in
accelerating the decline in lung function [28-30].
The pathogenicity of SM and AX in CF is not yet estab-
lished, although an association of these microorganisms
with pulmonary exacerbation has been reported. SM
chronic infection in our patients does not further influ-
ence clinical outcomes.
This study shows that there is no treatment of choice for
multidrug-resistant organisms. Therefore, synergistic anti-
biotic combinations may be useful for identifying the best
therapeutic action against multiresistant strains.
Conclusion
Our data emphasize the crucial role of microbiological
methods in defining possible therapeutic strategies that
may help to guide antibiotic therapy regimes in CF
patients. The short follow-up period and the small
number of some groups of patients infected with individ-
ual strains don't allow to define survival analysis and to
correlate microbiological data to clinical outcomes
between groups of patients. Further longitudinal prospec-
tive studies are ongoing.
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